Worried about skyrocketing prescription drug costs? Medicare's new spending cap is bringing welcome relief to seniors, with 94% of high-cost users expected to save thousands.

It’s unclear what — if any — impact the Republican president’s executive order will have on millions of Americans who have private health insurance.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year.

According to the timeline laid out in President Donald Trump’s May 12 executive order, prescription drug price reductions would not happen "almost immediately." The order specifies a 30-day period to develop pricing targets for drugmakers,

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Senate Democrats and the Biden administration dropped plans to set drug price caps based on the amount paid in other high-income countries, during talks years ago to push through the law that empowered Medicare to negotiate down the cost of prescription medications.